Atossa Therapeutics Reports $18.1 Million Net Loss and Decreased Cash Reserves for First Half of 2026

Atossa Therapeutics, Inc. reported a net loss of $18.1 million for the six months ended June 30, 2026, compared to a net loss of $15.1 million for the same period in 2025. The company's total operating expenses increased to $18.6 million from $16.5 million year-over-year, primarily driven by higher general and administrative costs, which rose by 31% to $8.9 million. Research and development expenses remained relatively stable, totaling $9.7 million, reflecting a slight increase from $9.7 million in the prior year. The company did not generate any revenue during this period, maintaining its focus on developing its lead drug candidate, (Z)-endoxifen.

In terms of liquidity, Atossa's cash and cash equivalents decreased to $26.1 million as of June 30, 2026, down from $41.3 million at the end of 2025. The company raised $4.0 million in net proceeds from a registered direct offering in June 2026, which was part of its strategy to secure additional capital to fund ongoing operations. Despite this infusion, the company continues to face substantial doubt regarding its ability to continue as a going concern, as it has not yet established a sustainable revenue source to cover its operating costs.

Operationally, Atossa has been advancing its clinical programs, particularly for (Z)-endoxifen, which is currently in Phase 2 trials for various indications, including breast cancer and rare diseases. The company is also exploring potential applications of (Z)-endoxifen in treating Duchenne muscular dystrophy and McCune-Albright syndrome. As of June 30, 2026, Atossa had 9,979,298 shares of common stock outstanding, following a reverse stock split executed in February 2026, which aimed to enhance the stock's marketability.

The company has indicated that it will continue to seek additional capital resources through equity sales and potential short-term borrowings to support its clinical development efforts. Atossa's management remains focused on advancing its drug candidates through clinical trials while navigating the challenges of securing adequate funding in a volatile economic environment. The outlook for the company hinges on its ability to successfully complete its clinical trials and secure regulatory approvals, which are critical for future commercialization efforts.